{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:43:07Z","timestamp":1792716187928,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003500","name":"University of Padua","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lungcan.2026.109404","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:08:18Z","timestamp":1775840898000},"page":"109404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Dissecting the prognostic role of metabolic markers in lung neuroendocrine Tumors: The MONET study"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-6038","authenticated-orcid":false,"given":"Giulia","family":"Pasello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pigato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Mulargiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9492-2123","authenticated-orcid":false,"given":"Federica","family":"Ferrarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-3108","authenticated-orcid":false,"given":"Federica","family":"Pezzuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Schiavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2619-5945","authenticated-orcid":false,"given":"Daniela","family":"Scattolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-717X","authenticated-orcid":false,"given":"Alessandro Dal","family":"Maso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2998-5072","authenticated-orcid":false,"given":"Stefano","family":"Frega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-7441","authenticated-orcid":false,"given":"Andrea","family":"Dell\u2019Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Indraccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109404_b0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41379-021-00943-2","article-title":"Lung neuroendocrine neoplasms: recent progress and persistent challenges","volume":"35","author":"Rekhtman","year":"2022","journal-title":"Mod. Pathol."},{"issue":"14","key":"10.1016\/j.lungcan.2026.109404_b0010","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.3390\/cancers15143712","article-title":"Grade Progression and Intrapatient Tumor Heterogeneity as potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine Tumors","volume":"15","author":"Varghese","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109404_b0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13550-022-00900-3","article-title":"Value of [68Ga]Ga-somatostatin receptor PET\/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature","volume":"12","author":"Deleu","year":"2022","journal-title":"EJNMMI Res."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109404_b0020","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1053\/j.seminoncol.2010.10.015","article-title":"Molecular Imaging of Neuroendocrine Tumors","volume":"37","author":"Carrasquillo","year":"2010","journal-title":"Semin. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109404_b0025","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S1470-2045(17)30681-2","article-title":"Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial","volume":"18","author":"Ferolla","year":"2017","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109404_b0030","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1378\/chest.12-1108","article-title":"Everolimus Plus Octreotide Long-Acting Repeatable in patients with Advanced Lung Neuroendocrine Tumors","volume":"143","author":"Fazio","year":"2013","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109404_b0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of177 Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109404_b0040","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/annonc\/mdt009","article-title":"Multicentre phase II study of cisplatin\u2013etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study","volume":"24","author":"Le Treut","year":"2013","journal-title":"Ann. Oncol."},{"issue":"10212","key":"10.1016\/j.lungcan.2026.109404_b0045","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.lungcan.2026.109404_b0050","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.lungcan.2026.109404_b0055","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109404_b0060","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ejcts\/ezs174","article-title":"Surgical management of pulmonary large cell neuroendocrine carcinomas: a 10-year experience","volume":"43","author":"Fournel","year":"2013","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109404_b0065","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3390\/jcm11051461","article-title":"Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and challenges","volume":"11","author":"Andrini","year":"2022","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109404_b0070","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.jtho.2022.09.076","article-title":"PP01.50 EMERGE-201: phase 2 Basket Study of Lurbinectedin Monotherapy in Advanced or Metastatic Solid Tumors","volume":"18","author":"Spigel","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109404_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112393","article-title":"Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: a review with structure-activity relationship insights","volume":"199","author":"Puri","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.lungcan.2026.109404_b0080","doi-asserted-by":"crossref","first-page":"22894","DOI":"10.18632\/oncotarget.15284","article-title":"Intratumoral lactate metabolism in Barrett\u2019s esophagus and adenocarcinoma","volume":"8","author":"Huhta","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109404_b0085","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1172\/JCI69741","article-title":"Targeting lactate metabolism for cancer therapeutics","volume":"123","author":"Doherty","year":"2013","journal-title":"J. Clin. Investig."},{"issue":"28","key":"10.1016\/j.lungcan.2026.109404_b0090","doi-asserted-by":"crossref","first-page":"43492","DOI":"10.18632\/oncotarget.9523","article-title":"MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109404_b0095","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0022-2275(20)32566-9","article-title":"Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL","volume":"39","author":"Calvo","year":"1998","journal-title":"J. Lipid Res."},{"issue":"14","key":"10.1016\/j.lungcan.2026.109404_b0100","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1073\/pnas.91.14.6379","article-title":"Fatty acid synthesis: a potential selective target for antineoplastic therapy","volume":"91","author":"Kuhajda","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109404_b0105","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nm0302-289","article-title":"Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy","volume":"8","author":"Pai","year":"2002","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109404_b0110","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/carcin\/bgp014","article-title":"The COX-2\/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment","volume":"30","author":"Greenhough","year":"2009","journal-title":"Carcinogenesis"},{"issue":"21","key":"10.1016\/j.lungcan.2026.109404_b0115","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1073\/pnas.200367597","article-title":"Intracellular unesterified arachidonic acid signals apoptosis","volume":"97","author":"Cao","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109404_b0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12964-024-02018-6","article-title":"Glutamine and cancer: metabolism, immune microenvironment, and therapeutic targets","volume":"23","author":"Nan","year":"2025","journal-title":"Cell Commun. Signaling"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109404_b0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1753-4887.1990.tb02967.x","article-title":"Is Glutamine a Conditionally Essential Amino Acid?","volume":"48","author":"Lacey","year":"2009","journal-title":"Nutr. Rev."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109404_b0130","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3390\/cancers14030553","article-title":"Advancing Cancer Treatment by Targeting Glutamine Metabolism\u2014A Roadmap","volume":"14","author":"Halama","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109404_b0135","doi-asserted-by":"crossref","first-page":"S1099","DOI":"10.1016\/j.jtho.2021.08.500","article-title":"P47.07 KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1\/NRF2-Mutated Non-Squamous Metastatic NSCLC","volume":"16","author":"Spigel","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109404_b0140","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.3390\/cancers14102552","article-title":"Monocarboxylate Transporters 1 and 4 and Prognosis in Small Bowel Neuroendocrine Tumors","volume":"14","author":"Hiltunen","year":"2022","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.lungcan.2026.109404_b0145","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1073\/pnas.1600007113","article-title":"Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors","volume":"113","author":"Krampitz","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109404_b0150","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/cancers12102968","article-title":"LAT-1 and GLUT-1 Carrier Expression and its Prognostic Value in Gastroenteropancreatic Neuroendocrine Tumors","volume":"12","author":"Sampedro-N\u00fa\u00f1ez","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109404_b0155","article-title":"Elevated Serum Amino Acids Induce a Subpopulation of Alpha Cells to Initiate Pancreatic Neuroendocrine Tumor Formation","volume":"1","author":"Smith","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.lungcan.2026.109404_b0160","doi-asserted-by":"crossref","unstructured":"Br\u00e4utigam K, Straub J, Bihi AK, Maire RS, Avanthay S, Fillipova K, et al. Dual inhibition of lactate transporters MCT1 and MCT4 in pancreatic neuroendocrine tumors targets metabolic heterogeneity and functional redundancy. 2025.","DOI":"10.1101\/2025.01.31.635625"},{"issue":"18","key":"10.1016\/j.lungcan.2026.109404_b0165","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.3390\/cancers16183179","article-title":"Metabolomic Profiling of Pulmonary Neuroendocrine Neoplasms","volume":"16","author":"Boullier","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109404_b0170","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2026.109404_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1070505","article-title":"Metabolic classification of non-small cell lung cancer patient-derived xenografts by a digital pathology approach: a pilot study","volume":"13","author":"Ferrarini","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109404_b0180","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12022-023-09755-3","article-title":"Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: past, present, and Future","volume":"34","author":"La Rosa","year":"2023","journal-title":"Endocr. Pathol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109404_b0185","doi-asserted-by":"crossref","DOI":"10.1590\/1806-9282.20240398","article-title":"Effect of Ki-67 proliferation index on survival in large cell neuroendocrine carcinoma of the lung","volume":"70","author":"Duygulu","year":"2024","journal-title":"Revista Da Associa\u00e7\u00e3o M\u00e9dica Brasileira."},{"issue":"5930","key":"10.1016\/j.lungcan.2026.109404_b0190","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the Metabolic Requirements of Cell Proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109404_b0195","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2307\/2532740","article-title":"Maximally selected Rank Statistics","volume":"48","author":"Lausen","year":"1992","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109404_b0200","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr. Pathol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109404_b0205","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","article-title":"Lung and thymic carcinoids: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109404_b0210","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3892\/etm.2010.117","article-title":"Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer","volume":"1","author":"Kaira","year":"2010","journal-title":"Exp. Ther. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109404_b0215","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/modpathol.2009.6","article-title":"Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis","volume":"22","author":"Ozbudak","year":"2009","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lungcan.2026.109404_b0220","doi-asserted-by":"crossref","unstructured":"Eilertsen M, Andersen S, Al-Saad S, Kiselev Y, Donnem T, Stenvold H, et al. Monocarboxylate Transporters 1\u20134 in NSCLC: MCT1 Is an Independent Prognostic Marker for Survival. Koritzinsky M (ed.) PLoS ONE. 2014;9(9): e105038.","DOI":"10.1371\/journal.pone.0105038"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109404_b0225","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.21037\/tcr-20-3117","article-title":"High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer","volume":"10","author":"Tong","year":"2021","journal-title":"Transl. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109404_b0230","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1158\/1078-0432.CCR-12-2334","article-title":"SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival","volume":"19","author":"Hassanein","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109404_b0235","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.21873\/invivo.12520","article-title":"Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms","volume":"35","author":"Horita","year":"2021","journal-title":"In Vivo"},{"key":"10.1016\/j.lungcan.2026.109404_b0240","doi-asserted-by":"crossref","DOI":"10.1172\/JCI36843","article-title":"Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice","author":"Sonveaux","year":"2008","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109404_b0245","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1016\/j.celrep.2018.11.043","article-title":"Dual Inhibition of the Lactate Transporters MCT1 and MCT4 is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells","volume":"25","author":"Benjamin","year":"2018","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109404_b0250","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","article-title":"A phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in patients with Advanced Cancer","volume":"29","author":"Halford","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109404_b0255","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/modpathol.3880459","article-title":"Neuroendocrine Lung Tumors: Grade Correlates with Proliferation but not Angiogenesis","volume":"14","author":"Arbiser","year":"2001","journal-title":"Mod. Pathol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:22:24Z","timestamp":1782663744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":51,"alternative-id":["S0169500226004654"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109404","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dissecting the prognostic role of metabolic markers in lung neuroendocrine Tumors: The MONET study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109404","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109404"}}